SARS-CoV-2 Spike S2 Antibody (1034617) [Unconjugated]

Western blot shows Recombinant SARS-CoV-2 Spike S2 Subunit Protein (10584-CV) and Recombinant SARS-CoV-2 Spike (Active Trimer) Protein (10549-CV). PVDF membrane was probed with 2 µg/mL of Mouse Anti-SARS-CoV-2 Spike S2 Subunit Monoclonal Antibody (Catalog # MAB10557) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF018). A specific band was detected for SARS-CoV-2 Spike S2 Subunit at approximately 70 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Simple Western lane view shows recombinant SARS-CoV-2 Spike S1 RBD (receptor binding domain) protein (negative sample), recombinant SARS-CoV-2 Spike S1 subunit protein (negative sample), recombinant SARS-CoV-2 Spike S2 subunit protein, recombinant SARS-CoV-2 Spike S1 /S2 Subunit protein, and recombinant SARS-CoV-2 Nucleocapsid protein (negative sample), loaded at 0.2 mg/mL. Specific bands were detected for SARS-CoV-2 Spike S2 Subunit at approximately 91kDa and SARS-CoV-2 Spike S1 /S2 Subunit at approximately 230 kDa (as indicated) using 20 µg/mL of Mouse Anti-SARS-CoV-2 Spike S2 Subunit Monoclonal Antibody (Catalog # MAB10557) . This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

• Reactivity: V
• Applications: WB, Simple Western
• Clone: 1034617
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

SARS-CoV-2 Spike S2 Antibody (1034617) [Unconjugated] Summary

• Immunogen: Recombinant SARS-CoV2 Spike S2 Subunit
  Met697-Pro1213
• Specificity: Detects SARS-CoV-2 Spike S2 Subunit in direct ELISAs.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Simple Western 20 ug/mL
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SARS-CoV-2 Spike S2 Antibody (1034617) [Unconjugated]

• COVID-19
• S2 protein
• SARS-CoV-2 Spike
• SARS-CoV-2
• Spike glycoprotein Subunit 2
• Spike protein S2
• spike protein
• Spike S2 Subunit
• structural protein
• surface glycoprotein

Background

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein(S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into two distinct peptides, S1 and S2 subunits, is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for SARS-CoV-2 Spike S2 Antibody (MAB10557)(5)

Publications using MAB10557

• Khanzode, R;Soni, G;Srivastava, S;Pawar, S;Wadapurkar, R;Singh, A; Combinative workflow for mRNA vaccine development Biochemistry and biophysics reports 2024-09-01 [PMID: 39040540] (Western Blot, Human)
• Fujita, S;Plianchaisuk, A;Deguchi, S;Ito, H;Nao, N;Wang, L;Nasser, H;Tamura, T;Kimura, I;Kashima, Y;Suzuki, R;Suzuki, S;Kida, I;Tsuda, M;Oda, Y;Hashimoto, R;Watanabe, Y;Uriu, K;Yamasoba, D;Guo, Z;Hinay, AA;Kosugi, Y;Chen, L;Pan, L;Kaku, Y;Chu, H;Donati, F;Temmam, S;Eloit, M;Yamamoto, Y;Nagamoto, T;Asakura, H;Nagashima, M;Sadamasu, K;Yoshimura, K;Suzuki, Y;Genotype to Phenotype Japan (G2P-Japan) Consortium, ;Ito, J;Ikeda, T;Tanaka, S;Matsuno, K;Fukuhara, T;Takayama, K;Sato, K; Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236 EBioMedicine 2024-06-04 [PMID: 38838469] (Simple Western, Virus - SARS-CoV-2)
• Bekdash, R;Yoshida, K;Nair, MS;Qiu, L;Ahdout, J;Tsai, HY;Uryu, K;Soni, RK;Huang, Y;Ho, DD;Yazawa, M; Developing inhibitory peptides against SARS-CoV-2 envelope protein PLoS biology 2024-03-01 [PMID: 38483887] (Western Blot, Human)
• K Zekri-Nech, JJ Zamorano-L, C Reche, M Giner, A López-de-A, R Jiménez-Ga, AJ López-Farr, CH Martínez-M Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa Disease Markers, 2022-11-18;2022(0):1118195. 2022-11-18 [PMID: 36438904] (Western Blot, Human)
• Q Yang, A Kelkar, A Sriram, R Hombu, TA Hughes, S Neelamegha Role for N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 Spike maturation and viral infectivity Science Advances, 2022-09-23;8(38):eabq8678. 2022-09-23 [PMID: 36149962] (Flow Cytometry, Human)